Suven Life Sciences Ltd.

NSE: SUVEN  SECTOR: Pharmaceuticals & Drugs

96
-1.85 (-1.89%)

Price Summary

Today's High

₹ 99.55

Today's Low

₹ 95.5

52 Week High

₹ 115.8

52 Week Low

₹ 30.45

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.

Company Essentials

Market Cap

1221.9117888 Cr.

Enterprise Value

1222.8164888 Cr.

No. of Shares

12.7282478 Cr.

P/E

0

P/B

3.35

Face Value

₹ 1

Div. Yield

0%

Book Value (TTM)

₹  28.6555

CASH

1.1242 Cr.

DEBT

2.0289 Cr.

Promoter Holding

60%

EPS (TTM)

₹  -1.778

Sales Growth

-94.9540675822462%

ROE

-3.48448863915634 %

ROCE

-6.39576781991274 %

Profit Growth

-95.4109346708568 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1w1m3m6m1Yr3Yr5Yr

* Prices are based on daily market changes.

Valuation Chart 1w1m3m6m1Yr3Yr5Yr

* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

Sales Growth (in Cr.)

1 Year-94.95%
3 Year-70.18%
5 Year-51.2%

Profit Growth (in Cr.)

1 Year-135.09%
3 Year-148.11%
5 Year-166.13%

ROE%

1 Year-3.48%
3 Year7.51%
5 Year11.55%

ROCE %

1 Year-6.4%
3 Year10.39%
5 Year14.46%

Debt/Equity

0.0052

Price to Cash Flow

-11.81

Interest Cover Ratio

-47.0031464001481

CFO/PAT (5 Yr. Avg.)

1.99306912296395

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2021 60 0
Dec 2020 60 0
Sep 2020 60 0
Jun 2020 60 0
Mar 2020 60 0
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 11.7274500156003 days.
  • The company has a high promoter holding of 60%.

 Limitations

  • The company has shown a poor profit growth of -148.114550414313% for the Past 3 years.
  • The company has shown a poor revenue growth of -70.1786767712972% for the Past 3 years.
  • Company has a poor ROE of 7.50692780870509% over the past 3 years.
  • Company has negative cash flow from operations of -103.428.
  • The company has a low EBITDA margin of -26.4646455367947% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021
Net Sales 8.66 1.43 8.98 1.51 1.56
Total Expenditure 10.74 9.22 12.82 11.88 10.04
Operating Profit -2.08 -7.79 -3.84 -10.37 -8.48
Other Income 3 2.53 2.28 1.62 1.32
Interest 0.23 0.22 0.25 0.17 0.24
Depreciation 1.05 1.07 1.08 1.14 1.07
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.37 -6.55 -2.9 -10.05 -8.46
Tax 2.2 -2.47 -1 -1.91 0.05
Profit After Tax -2.56 -4.08 -1.9 -8.15 -8.51
Adjusted EPS (Rs) -0.02 -0.03 -0.01 -0.06 -0.07

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 499.52 543.53 625.26 285.67 14.41
Total Expenditure 369.95 378.19 388.89 233.56 49.68
Operating Profit 129.57 165.34 236.37 52.11 -35.26
Other Income 19.62 21.09 23.27 27.25 14.04
Interest 5.87 5.67 4.61 1.9 0.54
Depreciation 17.5 21.41 24.76 14.2 4.17
Exceptional Items 0 0 0 0 0
Profit Before Tax 125.82 159.36 230.27 63.25 -25.94
Tax 25.74 35.88 71.84 24.06 -12.18
Net Profit 100.08 123.47 158.43 39.19 -13.75
Adjusted EPS (Rs.) 7.86 9.7 12.45 3.08 -1.08

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 12.73 12.73 12.73 12.73 12.73
Total Reserves 610.74 718.8 853.97 388.99 374.95
Borrowings 41.64 25.93 2.22 1.78 1.08
Other N/C liabilities -1.1 2.28 27.97 22.73 10.99
Current liabilities 204.72 203.98 221.85 130.51 103.53
Total Liabilities 868.73 963.72 1118.75 556.74 503.28
Assets
Net Block 305.35 305.72 307.73 22.35 24.69
Capital WIP 7.2 9.72 24.74 0.02 0
Investments 23.05 65.08 102.3 136.36 241.81
Loans & Advances 6.16 6.37 16.84 0 91.25
Other N/C Assets 0 0.2 0.2 0 0
Current Assets 526.96 576.64 666.93 398.01 145.52
Total Assets 868.73 963.72 1118.75 556.74 503.28
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit Before Tax 125.82 159.36 230.27 63.25 -25.94
Adjustment 10.97 12.9 10.3 -4.88 18.22
Working Capital Changes -20.27 9.74 -92.26 -55.46 -92.93
Tax Paid -26.7 -34.71 -43.54 -14.92 -2.78
Operating Cash Flow 89.82 147.27 104.77 -12.01 -103.43
Investing Cash Flow -61.65 -352.61 -37.81 3.2 101.37
Financing Cash Flow -68.06 -30.37 -52.05 4.55 2.75
Net Cash Flow -39.9 -235.71 14.92 -4.27 0.69

Corporate Actions

Ratings & Research Reports

Company Presentations

Company News

Suven Life Sciences Stock Price Analysis and Quick Research Report. Is Suven Life Sciences an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Suven Life Sciences and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs -103.428 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Suven Life Sciences has a Debt to Equity ratio of 0.0052 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Suven Life Sciences , the EPS growth was -135.089364106987 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Suven Life Sciences has OPM of -244.634296932992 % which is a bad sign for profitability.
     
  • ROE: Suven Life Sciences have a poor ROE of -3.48448863915634 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Suven Life Sciences

X